Contrasting MaxCyte (NASDAQ:MXCT) and Syneos Health (NASDAQ:SYNH)

MaxCyte (NASDAQ:MXCTGet Rating) and Syneos Health (NASDAQ:SYNHGet Rating) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their profitability, valuation, earnings, analyst recommendations, risk, institutional ownership and dividends.

Institutional & Insider Ownership

54.9% of MaxCyte shares are owned by institutional investors. Comparatively, 94.6% of Syneos Health shares are owned by institutional investors. 5.4% of MaxCyte shares are owned by company insiders. Comparatively, 0.3% of Syneos Health shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Analyst Ratings

This is a breakdown of recent recommendations and price targets for MaxCyte and Syneos Health, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
MaxCyte 0 0 5 0 3.00
Syneos Health 0 1 6 0 2.86

Syneos Health has a consensus target price of $104.71, indicating a potential upside of 35.71%. Given Syneos Health’s higher probable upside, analysts clearly believe Syneos Health is more favorable than MaxCyte.

Earnings & Valuation

This table compares MaxCyte and Syneos Health’s revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
MaxCyte $33.89 million 16.32 -$19.08 million N/A N/A
Syneos Health $5.21 billion 1.52 $234.83 million $2.24 34.45

Syneos Health has higher revenue and earnings than MaxCyte.


This table compares MaxCyte and Syneos Health’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
MaxCyte -56.30% -11.11% -10.18%
Syneos Health 4.50% 12.69% 5.17%


Syneos Health beats MaxCyte on 8 of the 11 factors compared between the two stocks.

MaxCyte Company Profile (Get Rating)

MaxCyte, Inc. operates as a cell-based therapies and life sciences company in the United States and internationally. Its products include MaxCyte ATx, an electroporation platform for small to medium scale transfection; MaxCyte STx, a scalable electroporation technology for high yield transient expression of complex proteins, vaccines, and biologics; MaxCyte VLx, an instrument for large volume cell-engineering; and MaxCyte GTx, a clinically validated and scalable electroporation technology for complex cellular engineering. The company also provides ExPERT Pas that allows for seamless scale-up to bioreactor volumes for protein, antibody, VLP, and virus production; processing assembly supporting products, including electroporation buffers, and processing assembly workflow and loading racks; and cGMP PAs that offers the scales and quality assurance required for clinical research and production in GMP clean-room facilities. It has a clinical and commercial license agreement with Allogene Therapeutics, Inc. The company was incorporated in 1998 and is headquartered in Gaithersburg, Maryland.

Syneos Health Company Profile (Get Rating)

Syneos Health, Inc. provides biopharmaceutical outsourcing solutions company in North America, Europe, the Middle East, Africa, the Asia-Pacific, and Latin America. It operates through two segments, Clinical Solutions and Commercial Solutions. The Clinical Solutions segment offers services for the development of diagnostics, drugs, biologics, devices, and digital therapeutics in the Phase I to IV of clinical development. This segment also provides individual services, including product development and regulatory consulting, project management, protocol development, investigational site recruitment, clinical monitoring, technology-enabled patient recruitment and engagement, clinical home health, clinical trial diversity, biometric, and regulatory affair services. The Commercial Solutions segment provides commercialization services, including deployment solutions, communications solutions, such as public relations, advertising, and medical communication services; and consulting services to the pharmaceutical, biotechnology, and healthcare industries. The company was formerly known as INC Research Holdings, Inc. and changed its name to Syneos Health, Inc. in January 2018. Syneos Health, Inc. was incorporated in 2010 and is headquartered in Morrisville, North Carolina.

Receive News & Ratings for MaxCyte Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MaxCyte and related companies with's FREE daily email newsletter.